acceleration and conversion in connection with our acquisition of Biosite,
(e) A write-off in the amount of $0.3 million and $1.2 million during the
second quarter of 2008 and 2007, respectively, relating to inventory
write-ups recorded in connection with the acquisitions of Panbio Limited
and BBI Holdings Plc. during the first quarter of 2008 and Biosite, Inc
during the second quarter of 2007.
(f) A charge of $15.4 million associated with the write-off of debt
origination costs and a prepayment premium paid upon early extinguishment
of related debt during the 2007 quarter, in conjunction with our financing
arrangements related to our Biosite acquisition.
(g) A $1.9 million foreign currency gain realized on the settlement of
intercompany notes during the 2007 quarter.
(h) Tax effect on adjustments as discussed above in notes (b), (c), (d),
(e), (f) and (g).
(i) For the three months ended June 30, 2008 and 2007, potential dilutive
shares were not used in the calculation of diluted net loss per common
share under GAAP because inclusion thereof would be antidilutive.
(j) Included in the weighted average diluted common shares for the
calculation of net income per common share for the three months ended June
30, 2008, on an adjusted cash basis, are dilutive shares consisting of
1,926,000 common stock equivalent shares from the potential exercise of
stock options and warrants and potential dilutive shares consisting of
3,411,000 common stock equivalent shares from the potential conversion of
convertible debt securities. The net income per diluted share calculation
for the three months ended June 30, 2008, on an adjusted cash basis,
includes the add back of interest expense related to the convertible debt
of $0.8 million resulting in net income
|SOURCE Inverness Medical Innovations, Inc.|
Copyright©2008 PR Newswire.
All rights reserved